Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (9367)	9/7/2002 5:53:27 AM
From: Rocketman	Respond to of 9719

Still in the can waiting to bear fruit as far as I know. I don't really keep tabs on them at all these days. As I said before, I think the whole idea of Incyte doing drug develpment under the parent company was a strategic mistake and that it should have been spun off and made to raise additional capital on its own (ala DiaDexus). At least they seemed to have stopped losing massive amounts of money by constantly acquiring companies for way too much money that never panned out except to generate huge losses ala: Combion, Genome Systems, Hexagen, Synteni, Proteome and I know I'm forgetting one or two more... I think the capital markets have concurred given the constant drubbing of the stock since the new direction and management team was announce last November 26th, the stock has gone from the high-teens/low $20's to this weeks $4-$5 range. Of course what the hell do I know about strategy, I'm just a lowly operations oriented kinda guy. Should have played the dead cat bounce for a cool 20%+ gain this week. Rman